Literature DB >> 8563481

Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm.

S C Yeung1, R Go, A Balasubramanyam.   

Abstract

We administered potassium iodide and propylthiouracil per rectum, in conjunction with intravenous dexamethasone and propranolol, for emergent treatment of a patient in thyroid storm with small bowel obstruction. Shortly after initiation of this treatment, the patient successfully underwent two emergent surgical procedures for resection of an intestinal volvulus with advanced peritonitis. Serum levels of iodide and propylthiouracil showed substantial absorption of these drugs via the rectal route. Measurement of 24-h urinary-free iodide indicated that the bioavailability of potassium iodide delivered by retention enema was at least 40%. Parenteral iodide preparations have been unavailable in the past, and continue to be difficult to obtain emergently. Rectal administration of inorganic iodide is an effective, readily available and less expensive alternative to parenteral sodium iodide for patients in thyroid storm with upper gastrointestinal tract dysfunction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8563481     DOI: 10.1089/thy.1995.5.403

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  4 in total

Review 1.  Thyroid emergencies.

Authors:  Nicholas J Sarlis; Loukas Gourgiotis
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

Review 2.  Thyroid emergencies.

Authors:  Joanna Klubo-Gwiezdzinska; Leonard Wartofsky
Journal:  Med Clin North Am       Date:  2012-02-17       Impact factor: 5.456

3.  Parturient with Endocrine Disorders in the Intensive Care Unit.

Authors:  Akhil K Singh; Soumya Sarkar; Puneet Khanna
Journal:  Indian J Crit Care Med       Date:  2021-12

4.  Current and emerging treatment options for Graves' hyperthyroidism.

Authors:  Prakash Abraham; Shamasunder Acharya
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.